Relative Bioavailability of Pimasertib in Cancer Patients

Completed · Phase 1

Conditions studied: Neoplasms

In brief

This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).

Key facts

Study ID
NCT01992874
Run by
EMD Serono
People needed
38
Starts
2013-11-30
Expected to finish
2015-02-28
Last updated by the study team
2017-08-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.